Every Form 4 that Inhibikase Therapeutics Inc (IKT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IKT filings page.
Inhibikase Therapeutics, Inc. ten percent owner RA Capital Healthcare Fund, L.P. entered an Exchange Agreement on July 29, 2026, swapping 18,030,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 18,030,000 shares at $0.001 per share. After this disposition, the Fund holds 6,970,000 shares of Common Stock. The Pre-Funded Warrant is immediately exercisable, has no expiration date, and includes a 9.99% beneficial ownership limitation for the Fund and its Attribution Parties. RA Capital Management, L.P., its general partner and principals Peter Kolchinsky and Rajeev Shah are also reporting persons and each disclaims beneficial ownership beyond respective pecuniary interests.
Inhibikase Therapeutics director Dennis N. Berman exercised stock options covering 21,854 shares of common stock on July 30, 2026 at an exercise price of $1.26 per share. The fully vested options were converted, leaving 0 options from this grant and 21,854 common shares held directly.
Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock. The option has an exercise price of $1.91 per share and expires on June 26, 2036.
The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service as a director through that date. After this grant, Berman holds stock options for 155,000 underlying shares directly.
Inhibikase Therapeutics, Inc. director David Canner received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036.
The options vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, contingent on his continued board service. Following this award, Canner holds 155,000 derivative securities directly.
Inhibikase Therapeutics, Inc. director Arvind Kush received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and were awarded at no cost to the director.
The options vest on the earlier of June 26, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds stock options for 155,000 underlying shares directly.
Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036. Following this grant, he holds 155,000 options directly.
The options will vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, as long as he continues to serve as a director through that date. This is a compensation-related award, not an open-market share purchase or sale.
Inhibikase Therapeutics, Inc. director Vincent Aurentz received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.9100 per share and expire on June 26, 2036. They vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, subject to his continued board service.
Inhibikase Therapeutics, Inc. director Amit Munshi reported a compensation-related grant of stock options. He received options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share, with no cash paid for the grant itself.
The options vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, conditioned on his continued service as a director through that date. After this grant, his reported stock option holdings from this award total 155,000 options, which are scheduled to expire on June 26, 2036.
Inhibikase Therapeutics director Vincent Aurentz forfeited 255,299 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition and were subject to forfeiture if a milestone was not met by the first anniversary of the February 21, 2025 closing date.
On February 21, 2026, the milestone was determined not to have been achieved, triggering the return of all 255,299 shares to the issuer at no cost. After this issuer disposition, Aurentz directly holds 510,596 shares of Inhibikase Therapeutics common stock.
Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition completed on February 21, 2025, but were subject to a milestone that had to be met by the first anniversary of that closing date.
On February 21, 2026, the milestone was determined not to have been achieved, causing all 338,282 shares to be returned to the issuer for no consideration. Following this disposition to the issuer, Christopher directly holds 676,564 shares of Inhibikase common stock.
Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares. On February 21, 2026, 19,089 shares of common stock were returned to the company after a milestone related to the February 21, 2025 CorHepta Pharmaceuticals acquisition was not achieved. Munshi received no cash or other consideration for this disposition to the issuer.
Following the forfeiture, he holds 38,176 shares of common stock directly and 365,000 shares indirectly through the Amit Munshi Revocable Trust.
Inhibikase Therapeutics, Inc. reported a new stock option grant to its Chief Executive Officer and director, Mark T. Iwicki. On January 5, 2026, he was awarded a stock option covering 4,982,706 shares of common stock at an exercise price of $2.01 per share.
The option is described as a right to buy common stock and had no purchase price at grant. It becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and each vesting installment depends on his continued employment through that vesting date. The option relates to 4,982,706 underlying common shares and is scheduled to expire on January 5, 2036, if not exercised earlier.
Inhibikase Therapeutics reported that President & Head of R&D Cabell Christopher received a grant of stock options on January 5, 2026. The award covers 900,117 stock options, each with an exercise price of $2.01 per share, giving the right to buy common stock. According to the disclosure, the options vest in 36 equal monthly installments starting January 5, 2026, and vesting is conditioned on Christopher’s continued employment through each vesting date. Following this grant, Christopher beneficially holds 900,117 derivative securities directly.
Inhibikase Therapeutics reported an insider equity award for its Chief Financial Officer, David McIntyre. He received a stock option grant covering 986,319 shares of common stock at an exercise price of $2.01 per share on January 5, 2026. The option was granted at a cost of $0 on the grant date, so no shares were bought or sold in this transaction.
The option vests and becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and is scheduled to expire on January 5, 2036. Following this grant, McIntyre beneficially owns derivative securities representing 986,319 option rights held directly.
Sands Capital Life Sciences Pulse Fund II, L.P. filed a Form 4 reporting a purchase of 2,068,965 shares of Inhibikase Therapeutics, Inc. (IKT) common stock in an underwritten public offering on 11/21/2025 at $1.45 per share. Following this transaction, the fund reports holding 13,018,965 shares directly.
The filing is made jointly by related entities, including Sands Capital Alternatives, LLC and affiliates, with the reporting persons identified as a director and 10% owner of IKT. Footnotes explain that additional Series A-1 and Series B-1 warrants to purchase 5,475,000 and 10,068,120 shares of common stock, respectively, are not included in the reported beneficial ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership cap.